Luc Biedermann1, Gerhard Rogler. 1. Division of Gastroenterology and Hepatology, University Hospital Zürich, Rämistrasse 100, 8091, Zürich, Switzerland, luc.biedermann@usz.ch.
Abstract
UNLABELLED: The intestinal microbiota (previously referred to as "intestinal flora") has entered the focus of research interest not only in microbiology but also in medicine. Huge progress has been made with respect to the analysis of composition and functions of the human microbiota. An "imbalance" of the microbiota, frequently also called a "dysbiosis," has been associated with different diseases in recent years. Crohn's disease and ulcerative colitis as two major forms of inflammatory bowel disease, irritable bowel syndrome (IBS) and some infectious intestinal diseases such as Clostridium difficile colitis feature a dysbiosis of the intestinal flora. Whereas this is somehow expected or less surprising, an imbalance of the microbiota or an enrichment of specific bacterial strains in the flora has been associated with an increasing number of other diseases such as diabetes, metabolic syndrome, non-alcoholic fatty liver disease or steatohepatitis and even psychiatric disorders such as depression or multiple sclerosis. It is important to understand the different aspects of potential contributions of the microbiota to pathophysiology of the mentioned diseases. CONCLUSION: With the present manuscript, we aim to summarize the current knowledge and provide an overview of the different concepts on how bacteria contribute to health and disease in animal models and-more importantly-humans. In addition, it has to be borne in mind that we are only at the very beginning to understand the complex mechanisms of host-microbial interactions.
UNLABELLED: The intestinal microbiota (previously referred to as "intestinal flora") has entered the focus of research interest not only in microbiology but also in medicine. Huge progress has been made with respect to the analysis of composition and functions of the human microbiota. An "imbalance" of the microbiota, frequently also called a "dysbiosis," has been associated with different diseases in recent years. Crohn's disease and ulcerative colitis as two major forms of inflammatory bowel disease, irritable bowel syndrome (IBS) and some infectious intestinal diseases such as Clostridium difficilecolitis feature a dysbiosis of the intestinal flora. Whereas this is somehow expected or less surprising, an imbalance of the microbiota or an enrichment of specific bacterial strains in the flora has been associated with an increasing number of other diseases such as diabetes, metabolic syndrome, non-alcoholic fatty liver disease or steatohepatitis and even psychiatric disorders such as depression or multiple sclerosis. It is important to understand the different aspects of potential contributions of the microbiota to pathophysiology of the mentioned diseases. CONCLUSION: With the present manuscript, we aim to summarize the current knowledge and provide an overview of the different concepts on how bacteria contribute to health and disease in animal models and-more importantly-humans. In addition, it has to be borne in mind that we are only at the very beginning to understand the complex mechanisms of host-microbial interactions.
Authors: Maria G Dominguez-Bello; Elizabeth K Costello; Monica Contreras; Magda Magris; Glida Hidalgo; Noah Fierer; Rob Knight Journal: Proc Natl Acad Sci U S A Date: 2010-06-21 Impact factor: 11.205
Authors: Ernst Holler; Gerhard Rogler; Julia Brenmoehl; Joachim Hahn; Hans Herfarth; Hildegard Greinix; Anne M Dickinson; Gerard Socié; Daniel Wolff; Gottfried Fischer; Graham Jackson; Vanderson Rocha; Beate Steiner; Guenther Eissner; Jeorg Marienhagen; Juergen Schoelmerich; Reinhard Andreesen Journal: Blood Date: 2006-01-19 Impact factor: 22.113
Authors: Jussi Vaahtovuo; Eveliina Munukka; Mika Korkeamäki; Reijo Luukkainen; Paavo Toivanen Journal: J Rheumatol Date: 2008-06-01 Impact factor: 4.666
Authors: Ece Mutlu; Ali Keshavarzian; Phillip Engen; Christopher B Forsyth; Masoumeh Sikaroodi; Patrick Gillevet Journal: Alcohol Clin Exp Res Date: 2009-07-23 Impact factor: 3.455
Authors: Siobhain M O'Mahony; Julian R Marchesi; Paul Scully; Caroline Codling; Anne-Marie Ceolho; Eamonn M M Quigley; John F Cryan; Timothy G Dinan Journal: Biol Psychiatry Date: 2008-08-23 Impact factor: 13.382
Authors: Li Wen; Ruth E Ley; Pavel Yu Volchkov; Peter B Stranges; Lia Avanesyan; Austin C Stonebraker; Changyun Hu; F Susan Wong; Gregory L Szot; Jeffrey A Bluestone; Jeffrey I Gordon; Alexander V Chervonsky Journal: Nature Date: 2008-09-21 Impact factor: 49.962
Authors: Kirsten Tillisch; Emeran A Mayer; Arpana Gupta; Zafar Gill; Rémi Brazeilles; Boris Le Nevé; Johan E T van Hylckama Vlieg; Denis Guyonnet; Muriel Derrien; Jennifer S Labus Journal: Psychosom Med Date: 2017-10 Impact factor: 4.312
Authors: Aafke W F Janssen; Tom Houben; Saeed Katiraei; Wieneke Dijk; Lily Boutens; Nieke van der Bolt; Zeneng Wang; J Mark Brown; Stanley L Hazen; Stéphane Mandard; Ronit Shiri-Sverdlov; Folkert Kuipers; Ko Willems van Dijk; Jacques Vervoort; Rinke Stienstra; Guido J E J Hooiveld; Sander Kersten Journal: J Lipid Res Date: 2017-05-22 Impact factor: 5.922